跳至主要内容
临床试验/DRKS00020982
DRKS00020982已完成不适用

Retrospective Analysis of the Treatment Pathways in Patients with BRAF V600E positive, metastatic colorectal cancer - MORSE-CRC (Metastatic Colorectal Cancer Online Retrospective Evaluation)

Pierre Fabre Pharma GmbH (DE)Pierre Fabre Pharma Austria (AT)Pierre Fabre Pharma AG (CH)0 个研究点目标入组 48 人开始时间: 2020年3月31日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Male or female patient = 18 years
  • 2. Metastatic colorectal cancer (mCRC)
  • 3. BRAFV600E mutation confirmed by valid test method
  • 4. Initiated at least 2nd-line systemic treatment as per local treatment standard
  • 5. Start of 1st-line treatment after 01-Jan-2016
  • 6. Documentation of treatment with drugs registered for mCRC in the respective country at the time of treatment

排除标准

  • 1. BRAF test after initiation of 2nd-line treatment
  • 2. Other secondary stage III-IV tumor diseases or concomitant systemic treatment of any secondary tumor disease
  • 3. Pregnant or lactating patient during the documented treatment lines
  • 4. Participation in a clinical trial during the documented treatment lines

研究者

发起方
Pierre Fabre Pharma GmbH (DE)Pierre Fabre Pharma Austria (AT)Pierre Fabre Pharma AG (CH)

相似试验